Τετάρτη, 14 Μαΐου 2014

8th Outview Film Festival

15 – 25 Μαΐου 2014 Ταινιοθήκη της Ελλάδος
(Ιερά Οδός 48, Μετρό Κεραμεικός)
11 ημέρες queer κινηματογράφου
8th Outview Film Festival 
«Δεν πολιτεύεται, αλλά ασκεί πολιτική μέσα από την τέχνη»

«δεν πολιτεύομαι, θα μείνω αφοσιωμένος στον άντρα & στα βιβλία μου»
Αύγουστος Κορτώ 2014


Trailer:  

http://vimeo.com/94449892

Τιμές των εισιτηρίων:
Εισιτήριο προβολής: 5 ευρώ
Ημερήσιο εισιτήριο: 8 ευρώ
Εισιτήριο διαρκείας: 50 ευρώ

(Δεν θα υπάρξει προπώληση, τα ταμεία της Ταινιοθήκης θα είναι ανοιχτά καθημερινά από τις 17.00 (στις 15 Μαΐου θα είναι ανοιχτά από τις 19.00)

Το «δεν πολιτεύομαι», μου ακούστηκε ως «δεν παντρεύομαι» και το «θα μείνω αφοσιωμένος στον άντρα μου και στα βιβλία μου» μου ακούστηκε ως «θα κάνω τη επανάσταση μου»
Πόσο πλάκα έχει μια πρόταση που αν την έλεγε ένας ετεροφυλόφιλος θα ήταν πιο στερεοτυπική από ποτέ. 
Ζούμε σε εποχές που οι ανατροπές έρχονται από τις αυτοαναιρέσεις των δεδομένων. 
Γέλασα πάρα πολύ όταν μια φίλη, μου είπε «μα εγώ ως στρέιτ ποτέ δεν έχω πει θα μείνω αφοσιωμένη στον άντρα μου, πόσο μικροαστικό είναι αυτό που είπε ο Κορτω;»
Τι ακριβώς είναι μικροαστισμός πλέον στις μέρες μας; 
Την στιγμή που το lesbian.gr ξεπερνά τa 2.000.000 views εκ των οποίων το 54% είναι ζευγάρια και στρέιτ άντρες, την στιγμή που οι γκέι και οι λεσβίες απαιτούν δικαίως ένα σύμφωνο συμβίωσης και γεννάνε παιδιά και διεκδικούν το δικαίωμα στην υιοθεσία, την ιδία ακριβώς στιγμή οι στρειτ έχουν αποδείξει και βροντοφωνάζουν ότι ο γάμος δεν σημαίνει ευτυχία και ακριβώς την ίδια στιγμή  τα ανατολικά αγόρια και κορίτσια (οι «λαθρομετανάστες») αποτελούν αντικείμενο πόθου για ένα μεγάλο κομμάτι του πληθυσμού μας, αυτήν ακριβώς την στιγμή το ίδιο που ονομαζότανε «μικροαστισμός» μπορεί να αποτελέσει μια queer προοπτική για μια καλύτερη κοινωνία. 
Maria Cyber

8ο Outview Film Festival και φέτος έχει να παρουσιάσει το δυνατότερο πρόγραμμα του μέχρι σήμερα.  
Με πάνω από 70 ταινίες, με Masterclass, workshop, events, περισσότερα βραβεία, επώνυμους καλλιτέχνες και για πρώτη φορά τόσους πολλούς καλεσμένους σκηνοθέτες, με συνεργασίες με πρεσβείες, ινστιτούτα και δυνατά media, αποτελεί ένα κινηματογραφικό -και όχι μόνο- δρώμενο στην πόλη μας που άξια μπορεί να περηφανευτεί ότι η Αθήνα που ζούμε και αγαπάμε είναι μια πόλη προοδευτική ακόμα και μέσα στην κρίση. 
Το φετινό Outview Film Festival που φέτος κλείνει τα 8 χρόνια του, συμπίπτει με τις εκλογές. 
Το Outview ακόμα και αν δεν πολιτεύεται και μένει αφοσιωμένο πρωτίστως στην ποιότητα των ταινιών που φιλοξενεί, ασκεί πολιτική και ασκεί πολιτική σε μια χώρα που δυστυχώς ακόμα επιμένει να θεωρεί τον διαφορετικό σεξουαλικό προσανατολισμό μη αποδεκτό. 
Έτσι για το φετινό σύνθημα της αφίσας του, δανείζεται μια δήλωση που πυροδότησε έναν ακόμα δημόσιο «μίσους λόγο» και χαιρετά την δικαστική έκβαση που αυτός προκάλεσε ακόμα και αν για πρώτη φορά στα ελληνικά δεδομένα, είχαμε αμέσως μετά μια δήλωση μετάνοιας. 
Πάρτε μια γεύση από το υπέροχο programming του και βρεθείτε δίπλα μας ως επιβεβαίωση ότι μπορούμε να φτιάξουμε μια καλύτερη κοινωνία που να χωράει όλες τις διαφορετικότητες!


Εναρκτήρια ταινία Οι ταινίες έναρξης του φεστιβάλ προβάλλονται με την πολύτιμη στήριξη του Γαλλικού Ινστιτούτου της Αθήνας. 
Πρόκειται για το “Eastern Boys”, καθώς και τη μικρού μήκους ταινία “Price tag”. 
Ο γνωστός Γάλλος ηθοποιός Olivier Rabourdin (Αρπαγή, Μεσάνυχτα στο Παρίσι), ο οποίος πρωταγωνιστεί και στις δύο ταινίες, θα είναι παρών και θα τις προλογίσει

Λίγα λόγια για την υπόθεση:
Όμορφα κι ατίθασα αγόρια από την Ανατολική Ευρώπη: έρχονται από τη Ρωσία, την Ουκρανία, την Μολδαβία… 
Ο μεγαλύτερος δε φαίνεται να είναι πάνω από 25 ετών, όσο για το μικρότερο... δεν υπάρχει τρόπος να ξέρουμε στα σίγουρα την ηλικία του. 
Περνάνε όλη τους την ημέρα στο σταθμό Gare du Nord στο Παρίσι. 
Η φαντασία θέλει να τους ονειρεύεται ως εκδιδόμενους άντρες. 
Έτσι λοιπόν κι ο Daniel, ένας διακριτικός κύριος γύρω στα πενήντα, έχει βάλει στο μάτι έναν από αυτούς τους νεαρούς, τον Marek.
Κάποια στιγμή, επιτέλους, βρίσκει το κουράγιο να πάει να του μιλήσει και ο νεαρός συμφωνεί να ακολουθήσει τον Daniel την επόμενη μέρα στο σπίτι του… 
Όμως ο Μάρεκ δε φτάνει μόνος του και μία ολόκληρη περιπέτεια ξεκινά, ένα ταξίδι βίας, πάθους, ανατροπών, ερωτικών και κυρίως ανθρώπινων δεινών και ηδονών ξετυλίγονται με φόντο ένα σπίτι στο Παρίσι.

“Τολμηρό, ρεαλιστικό, τρυφερό, αφοπλιστικό, το «Eastern Boys» του Ρομπέν Καμπιγιό δεν είναι (μόνο) μια ταινία για τους μετανάστες ή τον πληρωμένο έρωτα, αλλά ένας οδηγός επιβίωσης που ίπταται πάνω από τα ταμπού και την εύκολη κριτική.” Flix.gr

“Η δεύτερη ταινία του Robin Campillo είναι παράλληλα μια δραματική ταινία, μια τρυφερή ιστορία αγάπης και ένα αγωνιώδες θρίλερ” Variety


Ταινία Λήξης To φεστιβάλ θα κλείσει με την πολυβραβευμένη ταινία “Ιn the name of” που κέρδισε το Βραβείο Teddy στην Berlinale 2013

Ιn the name of (Malgorzata Szumowska, Poland, 102’, 2013)

Λίγα λόγια για την υπόθεση:
Το να είσαι γκέι και να το κρύβεις είναι μία τακτική που δυστυχώς απαντάται συχνά στις κλειστές ομοφοβικές μας κοινωνίες. 
Όταν όμως έχεις διαλέξει και το επἀγγελμα του ιερέα,  τα πράγματα περιπλέκονται. 
Ο πάτερ Adam αναλαμβάνει την ενορία ενός μικρού χωριού στην Πολωνία. 
Οργανώνει ένα κοινοτικό κέντρο για αγόρια και οι ντόπιοι τον δέχονται ως δικό τους. 
Όλοι τον εκτιμούν αφάνταστα αλλά δεν γνωρίζουν ότι ο ίδιος παλεύει με ένα δικό του μυστικό. 
Όταν θα γνωρίσει έναν εκκεντρικό νέο, ο πάτερ Adam θα αναγκαστεί επιτέλους να αντιμετωπίσει τα δικά του σκοτάδια…

ΠΡΟΒΟΛΕΣ:
  • Δωρεάν προβολή της ταινίας “Valentine Road” την Τετάρτη 21 Μαΐου στις 18.00 σε συνεργασία με το Ίδρυμα Ρόζα Λούξεμπουργκ. Η ταινία αποκαλύπτει την ομοφοβία, το σεξισμό, το ρατσισμό και το σχολικό εκφοβισμό (bullying) που επικρατεί στην Αμερικάνικη καθημερινότητα. Ταυτόχρονα, ξεμπροστιάζει ένα δικαστικό σύστημα το οποίο στέκεται ανίκανο να αντιμετωπίσει αυτήν την πραγματικότητα. Μετά την προβολή ακολουθεί συζήτηση με τη Νέλλη Καούνη (Colour Youth)
  • Η βραβευμένη στις Κάννες ταινία “ Stranger by the lake θα προβληθεί στην Αθήνα και σίγουρα θα προκαλέσει. Ο Αλέν Γκιροντί, με την τέταρτη μεγάλου μήκους ταινία του «Ο άγνωστος στη λίμνη», σάρωσε τις μνείες στο 66ο Φεστιβάλ Καννών, αποσπώντας εγκωμιαστικά σχόλια πολλών κριτικών και κερδίζοντας το βραβείο σκηνοθεσίας του τμήματος «Ένα κάποιο βλέμμα». 
  • Δεν θα λείψουν ούτε φέτος οι Ελληνικές συμμετοχές. Νέοι και παλιοί κινηματογραφιστές θα μας παρουσιάσουν τις ταινίες μικρού μήκους τους. Παράλληλα, θα δούμε κι ένα μικρό teaser από τη νέα ταινία που ετοιμάζει ο Χρήστος Βούπουρας “Εσπερινή Συμφωνία”  όπως και την τελευταία δουλειά του Άνθιμου Ανανιάδη.
  • Η πολυβραβευμένη ταινία “Out in the dark διεισδύει στη σχέση ενός Παλαιστίνιου με έναν Ισραηλινό και θίγει πολλά ζητήματα γύρω από την αγάπη και την, ενίοτε, επικινδυνότητά της. Θα σας θυμίσει το αξέχαστο “The Bubble”
  • Η νέα ταινία της Anna Margarita Albelo με την Guinevere Turner, “Who’s afraid of Vagina Wolf, θα κάνει την πρεμιέρα της στην Ελλάδα! Μία ταινία πάνω στις λεσβίες, τα μπερδέματα και τους έρωτές τους...
  • Η προσωπικότητα του φλεγματικού, Gore Vidal αποτυπώνεται στο εξαιρετικό ντοκιμαντέρ,Gore Vidal: United Stated of Amnesia”. Λίγοι έχουν επηρεάσει τον κόσμο της λογοτεχνίας, του κινηματογράφου και της πολιτικής, όπως ο Gore Vidal. Εμπεριέχοντας μοναδικές συνεντεύξεις με τον ίδιο τον Gore Vidal, το ντοκιμαντέρ παρουσιάζει ένα πορτραίτο αυτού του ζωντανού θρύλου του Αμερικάνικου Φιλελευθερισμού.
  • Θα μάθουμε για τον Άλαν Τούρινγκ, τον εμπνευστή και δημιουργό της φερώνυμης υπολογιστικής μηχανής που θεωρείται ο πρόδρομος των σημερινών περίπλοκων υπολογιστών. Αυτή η μαθηματική ευφυία υποβλήθηκε σε χημικό ευνουχισμό επειδή ήταν ομοφυλόφιλος.  Μαθαίνουμε για την πρωτοποριακή σκέψη και τη σεξουαλικότητά του στην ταινία “Codebreaker”.
  • Θα δούμε την εξαιρετική ταινία από την Γερμανία, “Free Fall” για έναν διχασμένο αστυνομικό που πρέπει να επιλέξει μεταξύ της εγκύου γυναίκας του και  του νέου του έρωτα.
  • Θα μαγευτούμε με τις μουσικές του Antony, από τους “Antony & the Johnsons” στο ντοκιμαντέρ, “Turning”.
  • Θα γελάσουμε με την νέα κωμωδία “G.B.F.” — ειδικά αν είμαστε λάτρεις του Glee. Η ταινία γνώρισε τεράστια επιτυχία όταν κυκλοφόρησε στις ΗΠΑ!
  • Θα προβληματιστούμε και θα συγκινηθούμε με τους ήρωες του “Pit Stop”, μιας ταινίας που έκανε πρεμιέρα στο Sundance Festival. Γιατί τελικά εκεί που δεν το περιμένεις έρχεται ο έρωτας της ζωής σου...
  • Στο “The Dog” θα μάθουμε για τον John Wojtowicz, τον άνθρωπο για τον οποίο γυρίστηκε η ταινία “Σκυλίσια Μέρα” με τον Αλ Πατσίνο. Συγκρατείστε αυτή τη λεπτομέρεια: έκανε απόπειρα ληστείας για να πληρώσει την εγχείρηση αλλαγής φύλου του συντρόφου του. Αποτυπώνεται στην κάμερα το πορτραίτο αυτού του ξεχωριστού ανθρώπου, που εύκολα θα μπορούσαμε να χαρακτηρίσουμε ως αξιαγάπητο, ηρωικό και σίγουρο ως αυτοκαταστροφικό.
  • Η ζωή του ακτιβιστή Buck Angel αποτυπώνεται στα ντοκιμαντέρ “Sexing the Transman” και “Mr. Angel”. Πρωτοποριακά ντοκιμαντέρ που εξετάζουν την FTM (Female to Male) σεξουαλικότητα.

EVENTS
Queer parties και events για όλα τα γούστα!


ΚΑΛΕΣΜΕΝΟΙ:
  • Ο Olivier Rabourdin θα παρουσιάσει την ταινία έναρξης “Eastern Boys” στην οποία πρωταγωνιστεί.
  • Η Patricia Field θα παρουσιάσει την ταινία “The Little House That Could”, ένα ντοκιμαντέρ για τον Οίκο μόδας της Field.
  • O σκηνοθέτης Yariv Mozer, μετά το επιτυχημένο ντοκιμαντέρ “The Invisible Men” που είδαμε στο Outview 2013, επιστρέφει με τη νέα του ταινία “Snails in the rain”, η οποία έκανε πρεμιέρα στο Φεστιβάλ του Τελ Αβίβ και έχει λάβει τις καλύτερες κριτικές!
  • Ο σκηνοθέτης Chris Belloni θα παρουσιάσει το ντοκιμαντέρ του, “I am gay and muslim”, ένα ντοκιμαντέρ για την ομοφυλοφιλία και τα γκέι δικαιώματα στον Ισλαμικό κόσμο.
  • O Lawrence Ferrara θα παρουσιάσει το προκλητικό του ντοκιμαντέρ για την αρρενωπότητα και την γκέι αντρική σεξουαλικότητα, “ Power erotic”.
  • Οι Angie West, Jackie Nunn και Bonnie Rae Brickman θα παρουσιάσουν τις ταινίες μικρού μήκους “Mark Bunyan: Very Nearly Almost Famous” και “Angie & Jackie Final Cut
  • Η σκηνοθέτρια J. Jackie Baier θα παρουσιάσει την ταινία “Julia” και το "Fucking Different XXY".
  • Ο σκηνοθέτης Charles Lum θα παρουσιάσει την ταινία του “Age of consent” μετά από το θεαματικό της sold out στο Λονδίνο.
  • Ο παραγωγός Jurgen Brunning θα παρουσιάσει τη νέα του παραγωγή “And you Belong” μια ταινία για το queer συγκρότημα “Scream Club” και θα παραδώσει ένα workshop “Πώς να δημιουργήσετε εναλλακτικό post porn”
  • H σκηνοθέτρια Jena Serbu και η παραγωγός Dawn Smith θα παρουσιάσουν τη νέα τους ταινία μικρού μήκους, “Sugar cookie”, μια ταινία που παίζει με την ιδέα της μονογαμίας και του ερωτικού παιχνιδιού.
  • Η σκηνοθέτρια Yulia Matsiy  θα παρουσιάσει το επίκαιρο ντοκιμαντέρ της, “They hate me In vain - LGBT christians in today's Russia”, το πρώτο ντοκιμαντέρ που ασχολείται με την καθημερινότητα που βιώνουν οι LGBT χριστιανοί στην Ρωσία.
  • Και φυσικά οι έλληνες κινηματογραφιστές μας που θα παρουσιάσουν τις νέες τους ταινίες: Νίκος Κυρίτσης, Ορέστης Μαλτέζος, Menelas, Maxim Cirlan, Μιχάλης Μαράβας.
Βραβεία

Φέτος θα δωθούν από το Outview Film Festival δύο βραβεία: 
“Καλύτερης Ταινίας”
και 
“Καλύτερου Ντοκιμαντέρ”. 

Η κριτική μας επιτροπή αποτελείται από τους:
  • Χρήστος Βούπουρας (Σκηνοθέτης)
  • Χρήστος Δήμας (Σκηνοθέτης)
  • Πέννυ Παναγιωτοπούλου (Σκηνοθέτρια)
  • Αύγουστος Κορτώ (Συγγραφέας)
  • Μέμη Κούπα (Σκηνοθέτρια)
Από την ομάδα του Antivirus, θα δωθεί το βραβείο της “Καλύτερης Ταινίας Μικρού Μήκους”.

Η απονομή βραβείων θα γίνει την 
Κυριακή 25 Μαΐου στο Shamone.

Και φυσικά το καλύτερο βραβείο το δίνετε εσείς μέσα από τις ψήφους σας στον κινηματογράφο, ψηφίζοντας για την καλύτερη ταινία!

Τις ημέρες του φεστιβάλ θα λειτουργεί μπαρ στην ταράτσα της Ταινιοθήκης όπου θα μπορείτε επίσης να απολαύσετε γευστικούς vegan (και μη) μεζέδες από τα πιο φρέσκα υλικά, ειδική προσφορά του www.biobox.gr

More info/schedule:
www.outview.gr
www.facebook.com/OutviewFestival 
ΜΕ ΤΗΝ ΥΠΟΣΤΗΡΙΞΗ

2014 STD Prevention Conference 09-12/Joul 2014 Atlanta USA

Center for Disease
cdc

May 7, 2014



2014 STD Prevention Conference
Dear Partners in Prevention,
The 2014 STD Prevention Conference is a little more than one month away! To help you prepare, the STD Prevention Conference Logistics Committee has some updates and reminders to share.
When making your travel arrangements for the Conference, don’t forget that there will be several pre-conference meetings taking place on Sunday, June 8 and Monday, June 9. 
The following sessions are open to all conference attendees:
Sunday, June 8
  • Program Science
  • Capacity Building for STD/HIV Prevention:  Defining a Role for Academia
  • Guidelines Development: Methods, Role and Impact
  • STI Vaccines: Toward Global STI Prevention and Control
Monday, June 9
  • Training: STD 101
  • STI Prevention Control in Latin America and the Caribbean
  • Site Visits ($20 fee)
  • Implementing PrEP in STD Clinics (Satellite)
  • Training: How to Link Adolescents to Good Community Providers of Sexual Healthcare: Tips for Implementing the Project Connect Model in Your Community (must register ahead of time)
The full conference agenda is now posted online. Highlights include:
  • King K. Holmes’ opening plenary talk entitled “Progress and Challenges in the Evolution of Sexual Health and STI Prevention.”
  • Interactive poster sessions with authors on Tuesday and Wednesday afternoons.
  • Plenary sessions on program science, social and behavioral issues, global health systems, and global challenges in bacterial STIs.
If you’d like to take advantage of the special hotel rate for conference attendees, remember to make hotel reservations before the end of the day, as the negotiated rate will increase after May 7.  If you are not able to join us in Atlanta, you can still be part of the conference by following the #STDConf14 hashtag on Twitter.
Special Note For Presenters:
Colleagues hosting oral presentations will have the opportunity to upload their slides before the conference. An email with further instructions will be sent in the near future.
Poster presenters should plan to be available from 12:00pm to 1:30pm on Tuesday, June 10 and Wednesday, June 11 to answer questions from Conference attendees.
Additional information for presenters- including recommended formatting for slides and posters- is available on the Information for Presenters section of the Conference website.
Please send any questions to STDConf@cdc.gov.

Regards,
Gail
Gail Bolan, M.D.
Director
Division of STD Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
1600 Clifton Road, Mailstop E-02
Atlanta, Georgia 30333
404-639-8260 Office
404-639-8609 Fax
gyb2@cdc.gov
footer

Η Act-Art-Project παρουσιαζει τον ΤΕΟ στο 2o QUEER FEST (11-05-2914)
























 












Την Κυριακή 11/05/2014 

στο θέατρο ΕΜΠΡOΣ

θα είμαστε όλοι εκεί 

στις 21:45

με σόου από τον Teo

σε μιά παραγωγή της  Act-Art-Project  


Σας περιμένουμε

Έβγαλαν ασθενή εκτός χειρουργείου επειδή δεν είχε να πληρώσει /

αναδημοσίευση από: 
Ανακοίνωση στην οποία αναφέρεται ένα απίστευτο περιστατικό, έδωσε στη δημοσιότητα το Μητροπολιτικό Κοινωνικό Ιατρείο Ελληνικού. 
Το success story συνέβη στον Ευαγγελισμό. 
Αναλυτικά η ανακοίνωση:
"Γίναμε αποδέκτες μια απίστευτης – ακόμα και για τα δικά μας δεδομένα – επώνυμης καταγγελίας από ασθενή, η οποία επιβεβαιώνεται και από κοινωνική λειτουργό. 

Πιο συγκεκριμένα την προηγούμενη εβδομάδα 54χρονος άνεργος και ανασφάλιστος πολίτης με βαριάς μορφής καρδιοπάθεια, που απαιτεί άμεση τοποθέτηση απιδινωτή, γιατί κινδυνεύει ανά πάσα στιγμή η ζωή του, εισήχθη μετά από μεγάλη προσπάθεια στο Γενικό Νοσοκομείο Αθηνών «Ευαγγελισμός».

Το νοσοκομείο αρχικά αρνούνταν να δεχτεί υπεύθυνη δήλωση ότι θα τους προσκομίσει ο ασθενής βιβλιάριο της πρόνοιας, όταν αυτό εκδοθεί, προκειμένου να προχωρήσουν στην επέμβαση τοποθέτησης.

Στην συνέχεια μετά την επιμονή των θεράποντων γιατρών του ασθενή, το νοσοκομείο δέχτηκε να προχωρήσουν στην επέμβαση διότι κινδύνευε η ζωή του.

Ενώ ο ασθενής έχει εισαχθεί στο χειρουργείο μπαίνει μέσα ο υπεύθυνος λογιστηρίου του νοσοκομείου και υποχρεώνει τους γιατρούς να διακόψουν την διαδικασία, που δεν είχε ξεκινήσει ακόμα, γιατί έπρεπε ο ασθενής να προσκομίσει πρώτα βιβλιάριο της πρόνοιας. 

Ο ασθενής ήταν ήδη με τον ορό στο χέρι και τον είχα ξυρίσει!

Είναι περιττό να αναφέρουμε ότι η κοινωνική υπηρεσία του Δήμου που έχει απευθυνθεί ο συγκεκριμένος ασθενής έχει κάνει ότι είναι δυνατόν για να μπορέσει να βγάλει άμεσα ο ασθενής βιβλιάριο της πρόνοιας, μέχρι τότε όμως ο ασθενής τι θα κάνει;

Θα περιμένει με κίνδυνο της ζωής του να κινηθούν οι βραδυκίνητες υπηρεσίες του δημοσίου;

Πως είναι δυνατόν ο υπεύθυνος λογιστηρίου να εισβάλει σε χειρουργείο και να ματαιώνει επέμβαση που είχαν κρίνει οι γιατροί ότι έπρεπε να γίνει ΑΜΕΣΑ διότι κινδύνευε η ζωή του αρρώστου;

Ας μας πει επιτέλους το Υπουργείο Υγείας που να απευθυνόμαστε για βοήθεια, αφού το ίδιο αδυνατεί να βοηθήσει και πλέον είναι ξεκάθαρο ότι οι ζωές των πολιτών είναι μόνο λογιστικά νούμερα και τίποτα παραπάνω.

Περιμένουμε απαντήσεις από το Υπουργείο Υγείας για αυτό το απαράδεκτο περιστατικό και απαιτούμε την ΑΜΕΣΗ εισαγωγή του ασθενούς στο νοσοκομείο για να γίνουν οι απαραίτητες ιατρικές πράξεις για το σοβαρό καρδιολογικό του πρόβλημα".

ΜΗΤΡΟΠΟΛΙΤΙΚΟ ΚΟΙΝΩΝΙΚΟ ΙΑΤΡΕΙΟ ΕΛΛΗΝΙΚΟΥ
ΩΡΕΣ ΛΕΙΤΟΥΡΓΙΑΣ
(ΔΕΥΤΕΡΑ-ΠΕΜΠΤΗ 10:00-20:00, ΠΑΡΑΣΚΕΥΗ 10:00-19:00) και (ΣΑΒΒΑΤΟ 10:00-14:00)
ΤΗΛΕΦΩΝΟ ΕΠΙΚΟΙΝΩΝΙΑΣ: 210 9631950
ΔΙΕΥΘΥΝΣΗ ΙΑΤΡΕΙΟΥ: εντός της πρώην Αμερικανικής βάσης
(δίπλα στο Πολιτιστικό Κέντρο Ελληνικού, 200 μέτρα από την Τροχαία Ελληνικού)

Ιστοσελίδα http://www.mkiellinikou.org
Email mkiellinikou@gmail.com

Χαμηλά στην κατάταξη για τα ΛΟΑΤ δικαιώματα η Ελλάδα

Η έκθεση και ο χάρτης των δικαιωμάτων των ΛΟΑΤ ατόμων στην Ευρώπη, γνωστός και ως χάρτης του ουράνιου τόξου, για το 2014, δόθηκε στη δημοσιότητα την Τρίτη από την Ilga-Europe.

Χαμηλά βρίσκεται η Ελλάδα στον χάρτη για το νομικό, πολιτικό και κοινωνικό πλαίσιο στην προάσπιση των δικαιωμάτων των ΛΟΑΤ ατόμων, με ποσοστό 31%. Η έκθεση και ο χάρτης των δικαιωμάτων των ΛΟΑΤ ατόμων στην Ευρώπη, γνωστός και ως χάρτης του ουράνιου τόξου, για το 2014, δόθηκε στη δημοσιότητα την Τρίτη από την Ilga-Europe. Παρατηρείται μια σταδιακή βελτίωση σε σχέση με το προηγούμενο έτος στις περισσότερες χώρες καθώς και ένα πισωγύρισμα σε άλλες.
  Η οργάνωση Ilga-Europe παρακολουθεί τις εξελίξεις σε 49 ευρωπαϊκές χώρες και κατατάσσει τα νομικά σημεία αναφοράς των κρατών σχετικά με την ισότητα των ΛΟΑΤ, σε κλίμακα 0%-100%. Οι βαθμολογίες σχετίζονται με το κατά πόσο οι πολιτικές και το νομικό σύστημα μιας χώρας έχει ειδικές αναφορές στον σεξουαλικό προσανατολισμό και την ισότητα των φύλων.
Η Ελλάδα, με 31%, βρίσκεται στην 12η θέση, όπως προκύπτει από τον χάρτη, μαζί με την Σλοβακία, τη Σερβία, την Ελβετία, το Λουξεμβούργο, την Πολωνία και τη Ρουμανία.
Δύο θέσεις ψηλότερα στην κατάταξη η Αλβανία με 38% την οποία ακολουθούν η Τσεχία, η Σλοβενία, η Ιρλανδία και η  Εσθονία με 35%.
Με μόλις 20%, τόσο η Κύπρος όσο και η Λετονία έχουν τη χαμηλότερη κατάταξη στην ΕΕ, ως προς τα δικαιώματα των ΛΟΑΤ ατόμων και ακολουθούνται από την Ιταλία και τη Λιθουανία.

Πατήστε πάνω στην εικόνα για να εμφανιστεί ολόκληρος ο χάρτης
Συγκεκριμένα για την Ελλάδα, στην ετήσια έκθεση της Ilga-Europe αναφέρεται μεταξύ άλλων, ότι η χώρα έχει καταδικαστεί από το Ευρωπαϊκό Δικαστήριο των Δικαιωμάτων Ανθρώπων για τη μη θέσπιση συμφώνου συμβίωσης για άτομα του ίδιου φύλου, από το 2008. «Η Ελλάδα έχει αποτύχει να τροποποιήσει τον σχετικό νόμο εξαιτίας συντηρητικών και θρησκευτικών πιέσεων», προστίθεται. Επίσης, επισημαίνεται η ύπαρξη «μέτρων αστυνομικής καταστολής κατά τρανς γυναικών».
Την καλύτερη επίδοση έχει η Μ. Βρετανία με 83% στην κατάταξη. Δεύτερο το Βέλγιο με 78% και τρίτη η Ισπανία με 73%.
Εντυπωσιακότερη είναι η βελτίωση της Μάλτας σχετικά με τα ΛΟΑΤ δικαιώματα, σε αντίθεση με αρκετά μικρά κράτη της Ευρώπης, ενώ η Ρωσία προωθεί ενεργά την ομοφοβία.
Η Ρωσία βρίσκεται στο τέλος της κατάταξης, μετά το Αζερμπαϊτζάν, την Αρμενία και το Μαρόκο.
Άλλες χώρες, όπως η Αρμενία, η Λευκορωσία, η Γεωργία και η Ουκρανία, παρουσιάζουν μια οπισθοδρόμηση ως προς τα δικαιώματα των ΛΟΑΤ με πολιτικές περιορισμού τους καθώς και νόμους περί «προπαγάνδας».
Παρόλο που τα δικαιώματα των ΛΟΑΤ ατόμων (λεσβιών, ομοφυλοφίλων, αμφισεξουαλικών και τρανσεξουαλικών) έχουν αναμφίβολα αποκτήσει μεγαλύτερη ορατότητα στην Ευρώπη, η πρόοδος σε νομικό, πολιτικό και κοινωνικό επίπεδο διαφέρει σημαντικά από τη μία χώρα στην άλλη, συμπεραίνεται στην έκθεση της Ilga-Europe.
«Η πρόοδος με όρους πραγματικών νομικών, πολιτικών και κοινωνικών αλλαγών διαφέρει σημαντικά από τη μία χώρα στην άλλη και εξαρτάται σε μεγάλο βαθμό από τα επίπεδα κοινωνικής αποδοχής καθώς και πολιτικής ηγεσίας και βούλησης, καθώς και από τη δύναμη της κοινωνίας των πολιτών στην κάθε χώρα», δήλωσε ο συν-προεδρεύων του εκτελεστικού συμβουλίου της Ilga-Europe.
- See more at: http://left.gr/news/hamila-stin-katataxi-gia-ta-loat-dikaiomata-i-ellada#sthash.Uk6L3fBW.GZjOkQAX.dpuf

Funding News from Fogarty Int'l Center at NIH / Department of Health and Human Services (...The HIVRAD program is designed to fund projects that further address hypotheses crucial to the design of an efficacious HIV/AIDS prophylactic vaccine. )

Part 1. Overview Information
Participating Organization(s)
National Institutes of Health (NIH)
Components of Participating Organizations
National Institute of Allergy and Infectious Diseases (NIAID)
Funding Opportunity Title
HIV Vaccine Research and Design (HIVRAD) Program (P01)
Activity Code
P01 Research Program Projects
Announcement Type
Reissue of PAR-12-087
Related Notices
None
Funding Opportunity Announcement (FOA) Number
PAR-14-206
Companion Funding Opportunity
None
Number of Applications
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.855, 93.856  
Funding Opportunity Purpose
The purpose of this Funding Opportunity Announcement (FOA) is to support multi-component, multi-disciplinary projects that address important scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive modeling of vaccine concepts in non-human primates may be included.  
Key Dates
Posted Date
May 5, 2014
Open Date (Earliest Submission Date)
June 29, 2014 
Letter of Intent Due Date(s)
June 29, 2014
Application Due Date(s)
July 29, 2014, by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
AIDS Application Due Date(s)
July 29, 2014
Scientific Merit Review
November  2014  
Advisory Council Review
January 2015  
Earliest Start Date
March 2015 
Expiration Date
July 30, 2014
Due Dates for E.O. 12372
Not Applicable
** ELECTRONIC APPLICATION SUBMISSION REQUIRED**

NIH’s new Application Submission System & Interface for Submission Tracking (ASSIST) is available for the electronic preparation and submission of multi-project applications through Grants.gov to NIH. 
Applications to this FOA must be submitted electronically; paper applications will not be accepted. ASSIST replaces the Grants.gov downloadable forms currently used with most NIH opportunities and provides many features to enable electronic multi-project application submission and improve data quality, including: pre-population of organization and PD/PI data, pre-submission validation of many agency business rules and the generation of data summaries in the application image used for review.
Required Application Instructions

It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts) and where instructions in the 
Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. 
Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. 
Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV
When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.  
Applications that do not comply with these instructions may be delayed or not accepted for review.

You will be sent to ASSIST to prepare and submit your application. Problems accessing or using ASSIST should be directed to the eRA Commons Help Desk.
Table of Contents
Part 2. Full Text of Announcement

Section I. Funding Opportunity Description
Background
Rates of infection with human immunodeficiency virus (HIV), the virus that causes Acquired Immunodeficiency Disease Syndrome (AIDS), have not abated and another 2.8 million new infections are estimated to have occurred worldwide in 2009. 
The continuing human and economic toll of HIV/AIDS requires a redoubled effort to develop a preventive HIV vaccine. Encouragingly, several recent results have bolstered enthusiasm for achieving this goal. 
The RV144 trial in a low-risk heterosexual population in Thailand was reported to show that the vaccine actually prevented infection in 31% of vaccinees during the scheduled three-year follow-up period, and that the vaccine effect appeared even stronger in the first year after completion of the immunization regimen. 
Non-human primate (NHP) studies with repeat-exposure mucosal challenge that transmits one or two SIV variants, just as observed for HIV in human sexual transmission, have shown that some vaccines can likewise induce abortive infection or prevent acquisition of virus in this analog model. 
In addition, multiple potent and broad neutralizing antibodies defining new targets on HIV gp120 have been isolated from HIV-infected individuals.
These recent results have opened new horizons and hypotheses that can be exploited for vaccine design and evaluation. 
The partially successful RV144 trial has introduced new ways to think about protection against HIV. 
Prior to RV144, because inducing broad neutralizing antibodies to produce “sterilizing” immunity was such an elusive goal, an interim goal had been to rely on T-cell immunity to suppress plasma viremia after exposure and infection.
 It now appears that vaccination can tip the balance against the virus in the early events after exposure, so the important time frame to focus on shifts from the weeks-long period it takes to establish and maintain setpoint plasma viremia to the first days after exposure, when the track and fate of the first penetrating virions are established.  
The case-control analysis of RV144 has implicated the level of IgG antibodies to a conformational V1V2 epitope(s) as affecting infection risk, though the function that may be performed by these antibodies to prevent infection is unclear at present. 
Since blocking the acquisition of infection is also observed in several NHP studies, these models can effectively investigate the generation, localization and mechanism of protective responses that operate early after transmission. 
Whether transmitted-founder viruses have properties that differentiate them in significant ways from the chronic viruses that have been used until now as sources of vaccine antigens is only beginning to be investigated. 
And the new epitopes described by recent antibody discoveries enlarge the options for focusing the generation of protective antibody responses. 
These developments provide fertile new avenues of research for improving vaccine design.
Objective:
 
The HIVRAD program is designed to fund projects that further address hypotheses crucial to the design of an efficacious HIV/AIDS prophylactic vaccine. 
Applications for five years of support should include plans that have advanced past the exploratory stage and include preliminary data. 
Less fully developed applications can request less than 5 years of support to establish feasibility. 
Applications aimed at developing or optimizing a specific vaccine platform should lay out a research pathway with clear decision points. 
Extensive modeling of vaccine concepts in non-human primates may be included.
Clinical studies involving human subjects or vaccine research focused solely on therapeutic applications are not considered appropriate and will not be funded under this FOA. 
For information on programs that support therapeutic vaccine development, please contact program staff.

Applications may address, but need not be limited to:
  • Approaches to elicit durable and broadly neutralizing antibodies against HIV and/or SIV
  • Identifying correlates of vaccine-induced immune protection to HIV/AIDS
  • HIV structural studies as they relate to designing HIV immunogens
  • Improved animal model systems (and challenge viruses) to address vaccine efficacy
  • Approaches to increase the immunogenicity of HIV antigens (e.g., novel adjuvants)
  • How vaccine design can better address the heterogeneity of HIV
  • Developing or improving viral or bacterial vaccine vectors
  • Determining how immune cells can be mobilized to the portal of infection
  • Investigations into the role of glycan structures on immunogenicity, antigenicity and infectivity
  • Investigations into innate immunity to alter the outcome of infection
Section II. Award Information
 
Funding Instrument
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
Application Types Allowed
New
Renewal
Resubmission  
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.
Funds Available and Anticipated Number of Awards
NIH intends to fund an estimate of 1-3 awards, corresponding to a total of $5M, for fiscal year 2015. Future year amounts will depend on annual appropriations.  
Award Budget
Application budgets are not limited but need to reflect the actual needs of the proposed project.  
Award Project Period
The scope of the proposed project should determine the project period. The maximum period is 5 years.  

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Section III. Eligibility Information

1. Eligible Applicants
Eligible Organizations
Higher Education Institutions
  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
  • Hispanic-serving Institutions
  • Historically Black Colleges and Universities (HBCUs)
  • Tribally Controlled Colleges and Universities (TCCUs)
  • Alaska Native and Native Hawaiian Serving Institutions
  • Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
Nonprofits Other Than Institutions of Higher Education
  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)
For-Profit Organizations
  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)
Governments
  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)
  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession
Other
  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American Tribal Organizations (other than Federally recognized tribal governments)
  • Faith-based or Community-based Organizations
  • Regional Organizations
  • Non-domestic (non-U.S.) Entities (Foreign Institutions)
Foreign Institutions
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are  eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are  allowed.
Required Registrations
Applicant Organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. 
All registrations must be completed prior to the application being submitted. 
Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. 
The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
  • Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
  • System for Award Management (SAM) (formerly CCR) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  • NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM. 
  • eRA Commons - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • Grants.gov – Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons.If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Eligible Individuals (Program Director/Principal Investigator)
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. 
Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
 
2. Cost Sharing
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
 
3. Additional Information on Eligibility
Number of Applications
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
NIH will not accept any application that is essentially the same as one already reviewed within the past thirty-seven months (as described in the NIH Grants Policy Statement), except for submission:
  • To an RFA of an application that was submitted previously as an investigator-initiated application but not paid;
  • Of an investigator-initiated application that was originally submitted to an RFA but not paid; or
  • Of an application with a changed grant activity code.
 
 
Section IV. Application and Submission Information

1. Requesting an Application Package
Applicants can access the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
Most applicants will use NIH’s ASSIST system to prepare and submit applications through Grants.gov to NIH. Applications prepared and submitted using applicant systems capable of submitting electronic multi-project applications to Grants.gov will also be accepted.
2. Content and Form of Application Submission
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. 
Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.
 
Letter of Intent
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
  • Descriptive title of proposed activity
  • Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
  • Names of other key personnel
  • Participating institution(s)
  • Number and title of this funding opportunity
The letter of intent should be sent to:
Peter R. Jackson, Ph.D.
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 3133, MSC-7616
6700B Rockledge Drive
Bethesda   MD  20892-7616 (U.S. Postal Service or regular mail)
Bethesda   MD  20817 (for express/courier service; non-USPS service)
Telephone: 301-496-8426
Email: pjackson@mail.nih.gov
 
Page Limitations
Component Types Available in ASSIST
Research Strategy/Program Plan Page Limits
Overall
12
Admin Core
  6
Core (use for Scientific Cores)
  6
Project (use for Research Projects)
12

Additional page limits described in the SF424 Application Guide and the Table of Page Limits must be followed.
Instructions for the Submission of Multi-Component Applications
The following section supplements the instructions found in the SF424 (R&R) Application Guide, and should be used for preparing a multi-component application.
The application should consist of the following components:
  • Overall: required
  • Administrative Core: required
  • Scientific Cores: optional
  • Research Projects: minimum of 2 required
Overall Component
When preparing your application in ASSIST, use Component Type ‘Overall’.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
SF424 (R&R) Cover (Overall)
Complete entire form.
PHS 398 Cover Page Supplement  (Overall)
Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component.
Research & Related Other Project Information (Overall)
Follow standard instructions.
Project/Performance Site Location(s) (Overall)
Enter primary site only.
A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.
Research & Related Senior/Key Person Profile (Overall)
Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this FOA) for the entire application.
A summary of Senior/Key Persons followed by their Biographical Sketches in the Overall section of the assembled application image in eRA Commons will be generated upon submission.
Budget (Overall)
The only budget information included in the Overall component is the Estimated Project Funding section of the SF424 (R&R) Cover.
A budget summary in the Overall section of the assembled application image in eRA Commons compiled from detailed budget data collected in the other components will be generated upon submission.
PHS 398 Research Plan  (Overall)
Introduction to Application: 
For Resubmission applications, an Introduction to Application is required in the Overall component. 
Specific Aims: 
 List in priority order, the broad, long-range objectives and goals of the proposed program. Concisely and realistically describe the hypothesis or hypotheses to be tested.  
Research Strategy:  
This narrative section summarizes the overall research plan for the multi-project application.  
The multi-project application should be viewed as a confederation of interrelated research projects, each capable of standing on its own scientific merit, but complementary to one another.  
This is an important section for it provides the group of investigators an opportunity to give conceptual wholeness to the overall program – by giving a statement of the general problem area and by laying out a broad strategy for attacking the problems.  
As the strategy develops, each project and core should be cited briefly as to its place in the overall scheme.  Summarize the special features in the environment and/or resources that make this application strong or unique.
Resource Sharing Plan: 
Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome 
Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.
Appendix: 
Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.   
Administrative Core
When preparing your application in ASSIST, use Component Type ‘Admin Core .’
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
SF424 (R&R) Cover (Administrative Core)
Complete only the following fields:
  • Applicant Information
  • Type of Applicant (optional)
  • Descriptive Title of Applicant’s Project
  • Proposed Project Start/Ending Dates
PHS 398 Cover Page Supplement (Administrative Core)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Administrative Core)
Human Subjects: 
Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.
Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.
Project Narrative:  Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components. 
Project /Performance Site Location(s) (Administrative Core)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Administrative Core)
  • In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Core Lead’ and provide a valid eRA Commons ID in the Credential field.
  • In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
  • Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
  • If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.   
Budget (Administrative Core)
Budget forms appropriate for the specific component will be included in the application package.
The administrative core budget should include a description of how research-related travel and training will be budgeted. Funding for the overall administrative efforts, including secretarial, and/or other administrative services, publication expenses resulting from collaborative efforts, and communication expenses, should be requested in this core. 
Budgets for the cost of travel and attendance by the to-be-named members of the Scientific Advisory Board (SAB) should be included in the budget for the Administrative Core.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
PHS 398 Research Plan  (Administrative Core)
Introduction to Application: 
For Resubmission applications, an Introduction to Application is allowed for each component.
Specific Aims:  
List in priority order, the broad, long-range objectives and goals of the proposed administrative core. In addition, state the core’s relationship to the program’s goals and how it relates to the individual research projects or other cores in the application.   
Research Strategy:  
An administrative core is a resource to the multi-project grant, providing overall management, coordination and oversight for the program. As part of the administrative core, provide an administrative plan that includes a description of the structure and roles of administrative staff, including the functions to be performed; how fiscal and other resources will be prioritized, allocated and managed; how communications will be facilitated. 
A fully developed and well-described Administrative Core plan is required even if no additional funds for the core are requested.
In addition within the Admin Core include the following:
Scientific Advisory Board
Plans for a Scientific Advisory Board (SAB), consisting of 3-4 independent subject matter experts, should be proposed in the application. 
 However, for new applications the names of proposed SAB members should not be included in the application. For a renewal application, provide the names of current and former SAB members but do NOT contact, recruit or name potential NEW SAB members. 
It is expected that the SAB members will attend annual meetings sponsored by the grantee to assist with interpretation of results and planning of future studies, and to assist NIAID Program Staff with assessing progress during the course of the project.
Annual Meetings
Plans for Annual site visits for the Program Officer, NIAID Program Staff and SAB, should be proposed in the application. All co-investigators should attend this meeting. 
During these visits it is expected that an update and summary of results generated from each project will be presented by the PD/PI, co-investigators and/or all pertinent staff. 
These presentations will be expected to include summaries of all goals and milestones achieved during the review period and a description of all problems encountered that may have an impact on the future direction of the scientific hypotheses.  
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.   
Planned Enrollment Report  (Administrative Core)
When conducting clinical research, follow all instructions for completing Planned Enrollment Reports as described in the SF424 (R&R) Application Guide. 
PHS 398 Cumulative Inclusion Enrollment Report (Administrative Core)
When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide. 
Research Project
When preparing your application in ASSIST, use Component Type ‘Project.’
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
SF424 (R&R) Cover (Research Project)
Complete only the following fields:
  • Applicant Information
  • Type of Applicant (optional)
  • Descriptive Title of Applicant’s Project
  • Proposed Project Start/Ending Dates
PHS 398 Cover Page Supplement (Research Project)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Research Project)
Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.
Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.
Project Narrative:  Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
Project /Performance Site Location(s) (Research Project)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Research Project)
  • In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.
  • In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
  • Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
  • If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.   
Budget (Research Project)
Budget forms appropriate for the specific component will be included in the application package.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
PHS 398 Research Plan  (Research Project)
Introduction to Application: 
 For Resubmission applications, an Introduction to Application is allowed for each component.
Specific Aims: List, in priority order, the broad long-range objectives and goals of the proposed project. Concisely and realistically describe the hypothesis or hypotheses to be tested. In addition, state the individual research project's relationship to the program’s goals and how it relates to other projects or cores.
Research Strategy:  
Use this section to describe how the proposed research will contribute to meeting the Project’s goals and objectives and explain the rationale for selecting the methods to accomplish the specific aims. 
In addition to stating the biological significance of the research, indicate the project's relevance to the primary theme of the application.
Organize the Research Strategy in the specified order as stated in the SF 424 (R&R) Application Guide.  Make sure to start each section with the appropriate section heading in order, Significance, Innovation, Approach, and include the appropriate information.  
 Experimental details should be cited using the Bibliography and Reference Cited section and need not be detailed in the Research Strategy.  
Preliminary Studies for new projects or progress reports for renewals must be included as part of the approach section, and must be contained within the page limits of the Research Strategy section.
Describe the research design conceptual procedures, and analyses to be used to accomplish the specific aims of the project. 
Describe any new methodology and its advantage over existing methodologies. 
Describe any novel concepts, approaches, tools, or technologies for the proposed studies. 
Discuss associations with clinical project(s). 
Discuss the potential difficulties and limitations of the proposed procedures and alternative approaches to achieve the aims. 
As part of this section, provide a tentative sequence or timetable for the project.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.   
Planned Enrollment Report  (Research Project)
When conducting clinical research, follow all instructions for completing Planned Enrollment Reports as described in the SF424 (R&R) Application Guide. 
PHS 398 Cumulative Inclusion Enrollment Report (Research Project)
When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide. 
 
Scientific Core
When preparing your application in ASSIST, use Component Type ‘Core.’
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
SF424 (R&R) Cover (Scientific Core)
Complete only the following fields:
  • Applicant Information
  • Type of Applicant (optional)
  • Descriptive Title of Applicant’s Project
  • Proposed Project Start/Ending Dates
PHS 398 Cover Page Supplement (Scientific Core)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Scientific Core)
Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.
Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.
Project Narrative:  Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components
 Project /Performance Site Location(s) (Scientific Core)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Scientific Core)
  • In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Core Lead’ and provide a valid eRA Commons ID in the Credential field.
  • In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
  • Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
  • If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.   
Budget (Scientific Core)
Budget forms appropriate for the specific component will be included in the application package.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
PHS 398 Research Plan  (Scientific Core)
Introduction to Application: 
For Resubmission applications, an Introduction to Application is allowed for each component.
Specific Aims:  
List in priority order, the broad, long-range objectives and goals of the proposed core(s). Concisely and realistically describe the hypothesis or hypotheses to be tested, if applicable. In addition, state the core’s relationship to the program’s goals and how it relates to the individual research projects or other cores in the application.
Research Strategy:  
Use this section to describe how the proposed core activities will contribute to meeting the program goals and objectives and explain the rationale for selection of the general methods and approaches proposed to accomplish the specific aims.  
In addition, this section should indicate the relevance of the core to the primary theme of the application. Each Core Service must support two or more projects in the program.
Organize the Plan in the specified order as stated in the SF 424 (R&R) Application Guide.  Make sure to start each section with the appropriate section heading in order, Significance, Innovation, Approach, and include the appropriate information.  
Experimental details should be cited using the Bibliography and Reference Cited section and need not be detailed in the Research Strategy.  
Preliminary Studies for new cores and progress reports for renewals must be included as part of the approach section and must be contained within the page limits of the Scientific Core Plan section.
Resource Sharing Plan: 
Individuals are required to comply with the instructions for the Resource Sharing Plans (Data Sharing Plan, Sharing Model Organisms, and Genome Wide Association Studies (GWAS)) as provided in the SF424 (R&R) Application Guide.
Appendix: 
Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.   
Planned Enrollment Report  (Scientific Core)
When conducting clinical research, follow all instructions for completing Planned Enrollment Reports as described in the SF424 (R&R) Application Guide. 
PHS 398 Cumulative Inclusion Enrollment Report (Scientific Core)
When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide. 
Foreign Institutions
Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.
 
3. Submission Dates and Times
Part I. Overview Information contains information about Key Dates. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies) using ASSIST or other electronic submission systems. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

4. Intergovernmental Review (E.O. 12372)
This initiative is not subject to intergovernmental review.
 
5. Funding Restrictions
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement

6. Other Submission Requirements and Information
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide.  Paper applications will not be accepted.
For information on how your application will be automatically assembled for review and funding consideration after submission go to: http://grants.nih.gov/grants/ElectronicReceipt/files/Electronic_Multi-project_Application_Image_Assembly.pdf.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically.

Important reminders:
All PD(s)/PI(s) and component Project Leads must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management (SAM). Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH. Applications that are incomplete will not be reviewed.
Post Submission Materials
Applicants are required to follow the instructions for post-submission materials, as described in NOT-OD-13-030.

Section V. Application Review Information
1. Criteria
Only the review criteria described below will be considered in the review process. 
As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Overall Impact - Overall
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the program   to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the program  proposed).
Review Criteria - Overall
Is the program as a whole scientifically compelling?  
Are there coordination and synergy of the individual research projects and cores towards the achievement of the central objectives of the program?  
Are the overall program goals significant and focused on studies that significantly address hypotheses crucial to the design of an efficacious HIV/AIDS prophylactic vaccine?  
Will the integration of the individual projects into a single program be more beneficial than pursuing each project independently?  
Does the Program Director(s)/Principal Investigator(s) have the leadership and scientific ability to develop an integrated and focused research program?  
Will the PD(s)/PI(s) devote adequate time and effort to the program?  
Is there adequate evidence of sufficient institutional support for the PD(s)/PI(s)?  
For applications designating multiple PD(s)/PI(s), are there adequate and appropriate coordination and communication among the PD(s)/PI(s)?
Scored Review Criteria - Research Projects
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. 
An application does not need to be strong in all categories to be judged likely to have major scientific impact. 
For example, a project  that by its nature is not innovative may be essential to advance a field.
Significance
Does the project  address an important problem or a critical barrier to progress in the field? 
If the aims of the project  are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? 
How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?   
Investigator(s)
Are the project lead, collaborators, and other researchers well suited to the project? 
If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? 
If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)?
If the project is collaborative or multi-project lead , do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?  
Do the project lead(s) possess demonstrated abilities to develop a program of integrated research projects with a well-defined central research focus? 
Do the investigators commit adequate time and effort to the program? 
Do the investigators possess the qualifications and experience necessary for the individual research projects?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? 
Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?   
Approach
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project ? 
Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? 
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 
1) the protection of human subjects from research risks, and 
2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?     
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?   
Overall Impact Administrative Core
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the Administrative Core to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the core proposed).
Review Criteria – Administrative Core
Reviewers will consider each of the criteria below in the determination of scientific and technical merit.  Is the administrative and organizational structure appropriate and adequate to the attainment of the objective(s) of the proposed program?  
Is the management plan for fiscal accountability and communication within the program appropriate?  Are the plans for coordination, problem identification and resolution, and the establishment of a strong collaborative environment for the program appropriate?  Are the experience, level of commitment, and availability of the Administrative Core Leader and administrative staff adequate to manage the program? 
Overall Impact - Scientific Cores (if applicable)
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the Scientific Core to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the core proposed).
Review Criteria – Scientific Core (if applicable)
Reviewers will consider each of the criteria below in the determination of scientific and technical merit: Is provision of resources and core services for the individual Research Projects critical and justified?  Is the relationship of a scientific core to the central focus of the overall program strong?  
Is the quality of the relevant facilities or services provided and criteria for prioritization and usage appropriate?  
Are the qualifications, competence, and commitment of the Core Leader and key personnel appropriate?
Additional Review Criteria - Overall Application, Research Projects and Cores
As applicable for the project  proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 
1) risk to subjects, 
2) adequacy of protection against risks, 
3) potential benefits to the subjects and others, 
4) importance of the knowledge to be gained, and 
5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
Inclusion of Women, Minorities, and Children 
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed.  
For additional information on review of the Inclusion section, please refer to the 
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 
1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 
2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 
3) adequacy of veterinary care; 
4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 
5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Resubmissions
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.  
Renewals
For Renewals, the committee will consider the progress made in the last funding period. 
Revisions
Not Applicable
Additional Review Considerations - Overall Application, Research Projects and Cores
As applicable for the project  proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Applications from Foreign Organizations
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 
1) the Select Agent(s) to be used in the proposed research, 
2) the registration status of all entities where Select Agent(s) will be used, 
3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 
4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
 
2. Review and Selection Process
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), convened by the NIAID  in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
  • May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
  • Will receive a written critique.
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Allergy and Infectious Diseases Council  . The following will be considered in making funding decisions:
  • Scientific and technical merit of the proposed project as determined by scientific peer review.
  • Availability of funds.
  • Relevance of the proposed project to program priorities.
3. Anticipated Announcement and Award Dates
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
 
Section VI. Award Administration Information

1. Award Notices
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. 
The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. 
These costs may be reimbursed only to the extent considered allowable pre-award costs.      
Any application awarded in response to this FOA will be subject to the DUNS, SAM Registration, and Transparency Act requirements as noted on the 
2. Administrative and National Policy Requirements
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. 
For these terms of award, see the  
More information is provided at 
Cooperative Agreement Terms and Conditions of Award
Not Applicable
 
3. Reporting
When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590 or RPPR) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.  
All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000.  
See the NIH Grants Policy Statement for additional information on this reporting requirement. 
Section VII. Agency Contacts
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
Application Submission Contacts
eRA Commons Help Desk (Questions regarding eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post submission issues)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
Finding Help Online: http://grants.nih.gov/support/index.html
TTY: 301-451-5939
Email: commons@od.nih.gov
Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading forms and application packages)
Contact Center Telephone: 800-518-4726
GrantsInfo (Questions regarding application instructions and process, finding NIH grant resources)
Telephone: 301-435-0714
TTY 301-451-5936
Email: GrantsInfo@nih.gov

Scientific/Research Contact(s)
Alan Schultz, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-292-6169
Email: schultzam@mail.nih.gov
Peer Review Contact(s)
Peter Jackson, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-496-8426
Email: pjackson@mail.nih.gov
Financial/Grants Management Contact(s)
Regina Kitsoulis
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-402-6245
Email: Kitsoulisre@mail.nih.gov

Section VIII. Other Information
Recently issued trans-NIH policy notices may affect your application submission. 
A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts
All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.